Beili He

No ORCID on file · 1 paper in corpus
observational 2024
Post-marketing safety profile of solriamfetol: A real-world disproportionality analysis using FDA adverse event reporting system (FAERS) database
Heliyon ·doi:10.1016/j.heliyon.2024.e38450

Solriamfetol is a selective dopamine and noradrenalin reuptake inhibitor applied in adult patients with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA). However, the post-marketing safety profi…